Jordan Kadish

News

Parsaclisib Displayed Significant Clinical Benefit, Manageable Safety Among Patients With R/R MCL

09/28/2023

Findings from the phase 2 CITADEL-205 trial indicated PI3Kδ inhibitor parsaclisib displayed significant clinical benefits and a manageable safety profile among patients with R/R mantle cell lymphoma.

Findings from the phase 2...

09/28/2023

Oncology

News

Golidocitinib Yields Acceptable Safety, Promising Efficacy Among Patients With Heavily Pretreated R/R Peripheral T-Cell Lymphomas

01/08/2024

Jordan Kadish ;

JAK1 selective inhibitor golidocitinib demonstrated tolerable safety and encouraging antitumor efficacy among patients with heavily pretreated R/R peripheral T-cell lymphomas.

JAK1 selective inhibitor...

01/08/2024

Oncology

News

ASTX727, Gilteritinib and Venetoclax Yielded High Remission Rates in Patients With R/R FLT3 Mutated AML Unfit for Chemotherapy

02/10/2023

Jordan Kadish ;

A phase 1/2 study found that the combination of ASTX727, gilteritinib, and venetoclax yielded high remission rates for patients with R/R FLT3-mutated AML or who are unable to receive chemotherapy.

A phase 1/2 study found that the...

02/10/2023

Oncology

News

Ciltacabtagene Autoleucel CAR−T-Cell Therapy for Patients With Multiple Myeloma

03/09/2023

Jordan Kadish ;

Ciltacabtagene autoleucel CAR-T-cell therapy produced favorable results among patients with relapsed/refractory multiple myeloma previously exposed to noncellular anti-BCMA therapies.

Ciltacabtagene autoleucel...

03/09/2023

Oncology

News

Atezolizumab Plus R-CHOP Therapy Among Patients With Previously Untreated DLBCL

07/25/2023

Jordan Kadish ;

Atezolizumab plus R-CHOP demonstrated durable clinical efficacy among patients with previously untreated DLBCL, however the benefit compared with a regimen of R-CHOP alone is likely to be insignificant, according to a phase 1b/2 trial.

Atezolizumab plus R-CHOP...

07/25/2023

Oncology

News

FDA Approves Momelotinib for Patients With Intermediate or High-Risk Myelofibrosis, Including Primary or Secondary MF, With Anemia

09/26/2023

Jordan Kadish ;

On September 15, 2023, the FDA granted approval for momelotinib for the treatment of intermediate or high-risk myelofibrosis, including primary and secondary myelofibrosis, for patients with anemia.

On September 15, 2023, the FDA...

09/26/2023

Oncology

News

Brentuximab Vedotin-AVD Yields Encouraging Efficacy and Tolerable Safety Among Patients With Classical Hodgkin Lymphoma and HIV

11/10/2023

Jordan Kadish ;

Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (AVD) yielded encouraging response rates and tolerable safety among patients with classical Hodgkin lymphoma and HIV.

Brentuximab vedotin with...

11/10/2023

Oncology

News

Haploidentical Donors as an Option for Patients With Myelodysplastic Syndrome

04/06/2023

Jordan Kadish ;

According to findings of a retrospective multicenter study, haploidentical donors may be a comparable option to HLA-matched unrelated donors for high-risk myelodysplastic syndrome, but have a higher incidence of acute GVHD.

According to findings of a...

04/06/2023

Oncology

News

Ibrutinib Demonstrated Efficacy Among Patients With Heavily Pretreated R/R MCL

05/01/2023

Jordan Kadish ;

Findings from a multicenter real-world retrospective analysis indicate that BTK inhibitor ibrutinib demonstrated good efficacy among patients with heavily pretreated R/R mantle cell lymphoma.

Findings from a multicenter...

05/01/2023

Oncology

News

R-CHOP Plus R-BAC Shows Potential as Induction Therapy for Transplant-Eligible Patients With MCL

09/06/2023

Jordan Kadish ;

The combination of R-CHOP and R-BAC demonstrated efficacy as a potential induction therapy option for transplant-eligible patients with mantle cell lymphoma, according to a retrospective analysis.

The combination of R-CHOP and...

09/06/2023

Oncology